Main Article Content

Rabab Aly *
Mohamed R. El-sharnoby
Adel A. Hagag
(*) Corresponding Author:
Rabab Aly |


Background: NRAS mutations are the most commonly detected molecular abnormalities  in hematologic malignancies, especially in those of myeloid origin. Objective: We aimed to determine the frequency of NRAS (NRAS ) mutation; and its prognostic significance in Egyptian children with acute myelogenous leukemia (AML). Subject and methods: Peripheral blood and bone marrow (BM) samples were taken from  39 de novo pediatric AML patients. Twenty subjects with matched age and sex were  selected as a control group. Samples from patients and control were analyzed for Exons 1, 2 of NRAS gene using genomic PCR-SSCP method. Results: NRAS mutations at the time of diagnosis was found in 6/39 (15.4%) AML  cases.  Patients with NRAS   had no significant  improved clinical  outcome than patients without mutation. Patients with NRAS  had similar complete remission (CR) rates compared with non mutated patients (66.7% vs. 69.5%, P=0.43).  Those in CR had a similar relapse rate regardless of the presence ofNRAS  (RR 33.4% vs. 30.2%, P=0.26).  However, an adverse prognosis for 3 year overall survival (OS) was associated with the presence of NRAS mutations. This adverse prognosis associated with NRAS mutations was also observed in terms  of disease-free survival (DFS)  (P=0.007). Univariate analysis showed that unfavorable prognostic factors for DFS were cytogenetic data (P = 0.005) and the NRAS gene mutation (P = 0.002).  Conclusion: NRAS  did not contribute to increase the disease recurrence, however NRAS  was found to be a poor prognostic factor for children with AML. Further
studies to confirm these findings are required because of the small number of patients with NRAS mutation.

Downloads month by month


Download data is not yet available.

Article Details